Drug Safety alert: CDSCO flags 78 drug samples
In its latest drug safety alert, the apex drug regulatory body, Central Drug Standard Control Organisation (CDSCO) has flagged 78 medicine batches for failing to qualify for a random drug sample test for December– 2023.
These include Montelukast Sodium and Levocetirizine Dihydrochloride Tablets manufactured by Bonsai Pharma, Multi-Vitamin Tablets (VITAJACKS-S TABLETS) manufactured by Jackson Laboratories, Telmisartan and Amlodipine Tablets IP (Zensartan-AM Tablets) manufactured by Windlass Biotech Limited, Telmisartan Tablets IP 40 mg (Telmibeck-40 Tablets) manufactured by Biocore Pharmaceuticals, Pregabalin Capsules IP (Pragavir Capsules) manufactured by Mayoford Pharma.
For the full story, check out the link given below:
CDSCO Drug Alert: 78 Drug Samples Including Alkem's Pan 40 Flagged
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.